Cargando…

Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares

OBJECTIVE: Whereas genetic susceptibility for systemic lupus erythematosus (SLE) has been well explored, the triggers for clinical disease flares remain elusive. To investigate relationships between microbiota community resilience and disease activity, we performed the first longitudinal analyses of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azzouz, Doua F, Chen, Ze, Izmirly, Peter M, Chen, Lea Ann, Li, Zhi, Zhang, Chongda, Mieles, David, Trujillo, Kate, Heguy, Adriana, Pironti, Alejandro, Putzel, Greg G, Schwudke, Dominik, Fenyo, David, Buyon, Jill P, Alekseyenko, Alexander V, Gisch, Nicolas, Silverman, Gregg J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Systemic Lupus Erythematosus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511964/ https://www.ncbi.nlm.nih.gov/pubmed/37365013 http://dx.doi.org/10.1136/ard-2023-223929

Ejemplares similares

Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal
por: Azzouz, Doua, et al.
Publicado: (2019)

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
por: Almeida-Brasil, Celline C, et al.
Publicado: (2022)

B Cell Tetherin: A Flow Cytometric Cell‐Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus
por: El‐Sherbiny, Yasser M., et al.
Publicado: (2020)

Blockade of Interferon‐γ Normalizes Interferon‐Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus
por: Welcher, Andrew A., et al.
Publicado: (2015)

Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
por: Gordon, Caroline, et al.
Publicado: (2016)

Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy‐Six–Week Phase III Parent Study in the United States
por: Furie, Richard A., et al.
Publicado: (2018)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study
por: Stohl, William, et al.
Publicado: (2017)

Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long‐Term Effects on Serum Immunoglobulins
por: Reddy, Venkat, et al.
Publicado: (2017)

Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti–Interferon‐γ Antibody, in Patients With Discoid Lupus Erythematosus
por: Werth, Victoria P., et al.
Publicado: (2017)

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty‐Four–Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Arm, Phase IIb Study
por: Merrill, Joan T., et al.
Publicado: (2018)

Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus‐Prone Mice
por: Oaks, Zachary, et al.
Publicado: (2016)

What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials
por: Furie, Richard, et al.
Publicado: (2021)

Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
por: Ginzler, Ellen, et al.
Publicado: (2021)

The Parasitic Worm Product ES-62 Targets Myeloid Differentiation Factor 88–Dependent Effector Mechanisms to Suppress Antinuclear Antibody Production and Proteinuria in MRL/lpr Mice
por: Rodgers, David T, et al.
Publicado: (2015)

Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials
por: van Vollenhoven, Ronald F., et al.
Publicado: (2016)

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
por: Jayne, David, et al.
Publicado: (2022)

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
por: Atisha‐Fregoso, Yemil, et al.
Publicado: (2020)

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus
por: Wallace, Daniel J., et al.
Publicado: (2019)

Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials
por: Gottenberg, Jacques‐Eric, et al.
Publicado: (2018)

Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab
por: Hoffman, Robert W., et al.
Publicado: (2017)

Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
por: Petri, Michelle, et al.
Publicado: (2023)

High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus
por: Reid, Sarah, et al.
Publicado: (2020)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
por: Brunner, Hermine I, et al.
Publicado: (2020)

Auxilin is a novel susceptibility gene for congenital heart block which directly impacts fetal heart function
por: Meisgen, Sabrina, et al.
Publicado: (2022)

Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial
por: Jourde-Chiche, Noemie, et al.
Publicado: (2022)

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
por: Clowse, Megan E. B., et al.
Publicado: (2017)

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
por: Hanly, John G., et al.
Publicado: (2019)

Novel Assays of Thrombogenic Pathogenicity in the Antiphospholipid Syndrome Based on the Detection of Molecular Oxidative Modification of the Major Autoantigen β(2)-Glycoprotein I
por: Ioannou, Yiannis, et al.
Publicado: (2011)

Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia
por: Lewis, Myles J, et al.
Publicado: (2012)

Lack of Effect of a Single Injection of Human C-Reactive Protein on Murine Lupus or Nephrotoxic Nephritis
por: Carlucci, Francesco, et al.
Publicado: (2010)

Oxidative Stress, T Cell DNA Methylation, and Lupus
por: Li, YePeng, et al.
Publicado: (2014)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

Association of FCGR3A and FCGR3B Copy Number Variations With Systemic Lupus Erythematosus and Rheumatoid Arthritis in Taiwanese Patients
por: Chen, Ji-Yih, et al.
Publicado: (2014)

Dual B Cell Immunotherapy Is Superior to Individual Anti-CD20 Depletion or BAFF Blockade in Murine Models of Spontaneous or Accelerated Lupus
por: Lin, WeiYu, et al.
Publicado: (2015)

A CD8 T Cell/Indoleamine 2,3-Dioxygenase Axis Is Required for Mesenchymal Stem Cell Suppression of Human Systemic Lupus Erythematosus
por: Wang, Dandan, et al.
Publicado: (2014)

Association of Systemic Lupus Erythematosus With Decreased Immunosuppressive Potential of the IgG Glycome
por: Vučković, Frano, et al.
Publicado: (2015)

Autoantibody‐Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity
por: Slight‐Webb, Samantha, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3dg7nk0pc6f4740ongs12sa3vo